Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer
Jared Deck,Marissa Hartley,Mohammad Akhter,Dongliang Wang,Jeffrey A Bogart,Michael D Mix
DOI: https://doi.org/10.2147/LCTT.S386344
2023-05-19
Lung Cancer: Targets and Therapy
Abstract:Jared Deck, 1 Marissa Hartley, 1 Mohammad Akhter, 1 Dongliang Wang, 2 Jeffrey A Bogart, 1 Michael D Mix 1 1 Department of Radiation Oncology, SUNY Upstate Medical University, Syracuse, NY, USA; 2 Department of Public Health and Preventive Medicine, SUNY Upstate Medical University, Syracuse, NY, USA Correspondence: Jared Deck, Department of Radiation Oncology, SUNY Upstate Medical University, 750 E Adams St, Syracuse, NY, 13202, USA, Tel +1 (315)-464-5276, Email Background: Prior studies suggest lymphopenia, systemic immune-inflammatory index, and tumor response all impact clinical outcomes in Stage III NSCLC. We hypothesized that tumor response after CRT would be associated with hematologic metrics and might predict clinical outcomes. Materials and Methods: Patients with stage III NSCLC treated at a single institution between 2011 and 2018 were retrospectively reviewed. Pre-treatment gross tumor volume (GTV) was recorded then reassessed at 1– 4 months post-CRT. Complete blood counts before, during and after treatment were recorded. Systemic immune-inflammation index (SII) was defined as neutrophil × platelet/lymphocyte. Overall survival (OS) and progression free survival (PFS) were calculated using Kaplan-Meier estimates, and compared with Wilcoxon tests. A multivariate analysis of hematologic factors impacting restricted mean survival was then performed using pseudovalue regression, accounting for other baseline factors. Results: 106 patients were included. After median follow-up of 24 months, median PFS and OS were 16 and 40 months, respectively. Within the multivariate model, baseline SII was associated with OS (p = 0.046) but not PFS (p = 0.09), and baseline ALC correlated with both PFS and OS (p = 0.03 and p = 0.02, respectively). Nadir ALC, nadir SII, and recovery SII were not associated with PFS or OS. Conclusion: In this cohort of patients with stage III NSCLC, baseline hematologic factors were associated with clinical outcomes including baseline ALC, baseline SII and recovery ALC. Disease response was not well correlated with hematologic factors or clinical outcomes. Keywords: lymphopenia, myelosuppression, chemoradiation, tumor response Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death in the United States and worldwide with 1.7 million deaths globally, representing over 18% of all cancer deaths. Despite recent advances, 3-year overall-survival (OS) is less than 60%. 1 Chemoradiotherapy (CRT) followed by immunotherapy has become a standard for definitive management of unresectable Stage III NSCLC. Oncologic therapies interact with the host immune system potentially altering clinical outcomes, though the complex interplay is not fully understood. The immune system plays a role in suppression of malignancy, but can be inhibited, allowing for cancer progression. Radiotherapy can enhance cancer cell antigenicity by upregulating DNA damage and cellular stress pathways, exposing immunogenic tumor-associated antigens to the immune system. 2,3 Conversely, multimodality treatment with radiation can induce lymphopenia 4–6 and dampen the immune response, because lymphocytes are key mediators of the response to cancer. Mature circulating lymphocytes are highly radiosensitive and exhibit significant DNA fragmentation at even low radiation doses (<1Gy). 7,8 Multiple studies have associated lymphopenia with a detrimental impact on clinical outcomes in some cancer types 5,6,9–11 while others have failed to show such a relationship. 4 It has been proposed that radiation dose to the host immune system is associated with worse clinical outcomes in patients with Stage III NSCLC. 12 The systemic immune-inflammatory index (SII = neutrophil × platelet/lymphocyte) is a marker that has been suggested to have prognostic influence in patients treated with locally advanced NSCLC, as well as other malignancies. 13 Standard radiotherapy for Stage III NSCLC targets not only gross disease but often includes additional margin for at-risk regions as well as uncertainties in planning or treatment delivery, resulting in collateral effects on health tissue, including tissue involved in the immune response. Recent evidence suggests tumor volume reduction as determined by modern RT image guidance such as cone beam computed tomography (CBCT) images may be correlated with clinical outcome. 14 In this retrospective study, we aimed to investigate the relationship between lymphopenia, SII, and disease response based on CT imaging following completion of definitive chemoradiation (CRT) in stage III NSCLC. We hypothesized that tumor response after CRT -Abstract Truncated-